Plant-based meat alternatives,
does it really help with Lower LDL cholesterol?
research showsThe grade is C. SWAP-MEAT randomized 38 people, and 36 completed two eight-week periods of animal meat and plant-based alternatives. TMAO was the registered primary outcome and LDL was prespecified secondary. The adjusted LDL difference was -10.8 mg/dL (95% CI -17.3 to -4.3). Beyond Meat funded trial operations, and the principal investigator disclosed an unrestricted research gift from Beyond Meat. NHLBI training support and Stanford CTSA infrastructure did not jointly fund trial operations.
ads claimPlant-based does not automatically mean low sodium or low saturated fat. This tested meat analogs, not beans or tofu.
Useful facts when choosing a product
- A representative 113-g Beyond Burger at the trial era had about 390 mg sodium, 0 g sugar, about 5 g saturated fat, 2 g fiber, and 20 g protein. Formulations and products change.
- Some alternatives contain more sodium than unseasoned meat, and saturated fat depends on formulation oils.
- Verdict 2074 is C with 50 points for red versus white meat and LDL; this verdict directly replaces animal meat with processed plant-based analogs.
Chamgap Semantic Classification Code
Candidate index · review held
F.replacing-animal-meat-with-processed-plant-based-meat-alternatives.food.ldl-cholesterol.reduce.UNKFoods and beverages > Replacing animal meat with processed plant-based meat alternatives > Food consumption > LDL cholesterol > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Crimarco crossed at least two daily servings of Beyond Meat products with beef, pork, and chicken periods. Thirty-six of 38 randomized participants completed both eight-week phases. TMAO was primary in the registry and analysis plan; LDL was prespecified secondary. The paper states that Beyond Meat funded the study and that the principal investigator received an unrestricted research gift from Beyond Meat. NHLBI training support and Stanford CTSA infrastructure did not jointly fund trial operations.
Why this is classified as C (50)
One manufacturer-funded crossover trial found a conventionally moderate LDL difference, but it was a prespecified secondary surrogate without comparable independent replication and was small and short, giving C with 50 points.
Counterpoint. C does not mean the products are moderately heart-healthy; it describes limited evidence for the LDL claim.
Rejudgment record. Cross-check applied — Assessed registry outcomes, adjusted LDL difference, approximate standardized magnitude, later randomized evidence, pooling, and funding
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Lower LDL versus animal meat | C | The pooled direction was favorable, with surrogate, product-heterogeneity, and industry-funding limits. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Crimarco A et al., 2020 SWAP-MEAT | Randomized crossover diet trial without washout | 38 randomized and 36 completers analyzed | Beyond Meat trial funding and products; NHLBI training and Stanford CTSA infrastructure support | Primary TMAO; prespecified secondary LDL | LDL 109.9 plus or minus 4.5 versus 120.7 plus or minus 4.5 mg/dL; adjusted difference -10.8 (-17.3 to -4.3) | Pivotal manufacturer-funded surrogate trial |
| Fernandez-Rodriguez R et al., 2025 systematic review and meta-analysis | Meta-analysis of adult randomized trials | Seven randomized trials for LDL | Mixed funding across included trials | LDL cholesterol | MD -0.25 mmol/L (95% CI -0.42 to -0.08), I-squared 65.8% | Indirect pooled estimate mixing products and comparators |
| Publicly funded RE-MAP trial | Eight-week randomized diet trial | 89 participants | Public funding | LDL cholesterol | Eight-week difference 0.0 mmol/L (95% CI -0.2 to 0.1) | Indirect evidence not counted as direct replication or conflict because products and control design differed |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-08-03).
Final verification and publication gate: Codex · Evidence date: 2026-08-03 · Corrections: none
Cite this verdict
[Chamgap] Plant-based meat alternatives x lower LDL versus animal meat — Evidence Grade C·50. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/plant-based-meat-alternatives-ldl-reduction/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.